A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C

Clinical Chemistry

Volumn 52, Issue 10, 2006, Pages 1887-1896

  Ngo, Yen ^a   Munteanu, Mona ^b   Messous, Djamila ^a   Charlotte, Frederic ^a   Imbert Bismut, Françoise ^a   Thabut, Dominique ^a   Lebray, Pascal ^a   Thibault, Vincent ^a   Benhamou, Yves ^a   Moussalli, Joseph ^a   Ratziu, Vlad ^a   Poynard, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Biopredictive   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INVASIVE MEASUREMENT; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

ALANINE TRANSAMINASE; ALPHA-MACROGLOBULINS; ANALYSIS OF VARIANCE; APOLIPOPROTEIN A-I; BILIRUBIN; BIOLOGICAL MARKERS; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HAPTOGLOBINS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

HEPATITIS C VIRUS;

EID: 33749138640     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.070961     Document Type: Article

References (47)

1. Afdhal NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 2003;37:972-4.
2. Dienstag J. The role of liver biopsy in chronic hepatitis C. Hepatology 2002;36:S152-60.
3. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-8.
4. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239-44.
5. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
6. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000;14:543-8.
7. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, et al. Role of liver biopsy in management of chronic hepatitis C: A systematic review. Hepatology 2002;36:S161-72.
8. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV-Fibrosure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004;3:8.
9. Imbert-Bismut F, Ratziu V, Laurence Pieroni L, Charlotte F, Benhamou Y, Poynard T, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-75.
10. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002;9:128-33.
11. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003;38:481-92.
12. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus-coinfected patients. AIDS 2003;17:1-5.
13. Thabut D, Simon M, Myers RP, Messous D, Thibaut V, Imbert-Bismut F, et al. Non-invasive prediction of fibrosis in patients with chronic hepatitis C [letter]. Hepatology 2003;37:1220-1.
14. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004; 10:1-6.
15. Castéra L, Vergniol J, Foucher J, Brigitte Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, FibroTest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50.
16. Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Portal I, Renou C, et al. Independent prospective multicenter validation of biochemical markers (FibroTest-ActiTest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C. Am J Gastroenterol 2006;101:547-55.
17. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003;49:450-4.
18. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004;50:1344-55.
19. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-95.
20. Forns X, Ampurdanes S, Sanchez-Tapias JM, Guilera M, Sans M, Sanchez-Fueyo A, et al. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol 2001; 35:265-71.
21. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998;28:930-8.
22. The METAVIR cooperative group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994;20:15-20.
23. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
24. Poynard T. Diagnosis method of inflammatory, fibrotic, or cancerous disease using biochemical markers. US Patent 6 631 330. October 7, 2003.
25. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, et al. A prospective assessment of the interlaboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002;2:3-7.
26. Imbert-Bismut F, Messous D, Thibaut V, Myers RB, Piton A, Thabut D, et al. Intralaboratory analytical variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004;42:323-33.
27. Munteanu M, Messous D, Thabut D, Imbert-Bismut F, Jouys M, Massard J, et al. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest). Comp Hepatol 2004;3:3.
28. Imbert-Bismut F, Messous D, Raoult A, Poynard T, Bertrand JJ, Marie PA, et al. Results transferability on RXL, ARX, X-P and, BN2 (Dade Behring) and modular DP (Roche Diagnostics) analysers; application to component assays of FibroTest and ActiTest. Ann Biol Clin (Paris) 2005;63:305-13.
29. Rosenthal-Allieri MA, Peritore ML, Tran A, Halfon P, Benzaken S, Bernard A. Analytical variability of the FibroTest proteins. Clin Biochem 2005;38:473-8.
30. Ferard G, Piton A, Messous D, Imbert-Bismut F, Frairi A, Poynard T, et al. Intermethod calibration of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) results: application to FibroTest and ActiTest scores. Clin Chem Lab Med 2006;44:400-6.
31. Pugh R, Murray-Lyon I, Dawson J, Pietroni M, Williams R. Transection of the oesophagus for bleeding oesophagus varices. Br J Surg 1973;60:646-9.
32. Wai CT, Greenson JK, Fontana RJ, Kalbfleish JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
33. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36:986-92.
34. Hintze JL. NCSS 2003 User Guide. Kaysville, UT: Number Cruncher Statistical Systems, 2003.
35. Vallin J, Meslé F. Tables de Mortalité Françaises pour les XIXe et XXe Siècles et Projections pour le XXIe Siècle. Paris: Institut National d'Etudes Démographiques, 2001.
36. Ederer F, Heise H. Instructions to IBM 650 Programmers in Processing Survival Computations. Methodological Note No. 10, End Results Evaluation Section. Bethesda, MD: National Cancer Institute, 1959.
37. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
38. McClish DK. Analyzing a portion of the ROC curve. Med Decis Making 1989;9:190-5.
39. Zhou X, Obuchowski N, McClish D. Statistical Methods in Diagnostic Medicine. New York: John Wiley & Sons, 2002.
40. Khan MH, Farrell GC, Byth K, Lin R, Weltman M, George J, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000;31:513-20.
41. Guechot J, Serfaty L, Bonnand AM, Chazouilleres O, Poupon RE, Poupon R. Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol 2000;32:447-52.
42. Temple RJ. A regulatory authority's opinion about surrogate end-points. In: Nimmo WS, Tucker GT, eds. Clinical Measurement in Drug Evaluation, New York: John Wiley and Sons, Inc., 1995:1-2.
43. Kelloff GJ, Sigman CC. New science-based endpoints to accelerate oncology drug development. Eur J Cancer 2005;41:491-501.
44. Ferard G, Imbert-Bismut F, Messous D, Piton A, Ueda S, Poynard T, et al. A reference material for traceability of aspartate amino-transferase (AST) results. Clin Chem Lab Med 2005;43:549-53.
45. D'Arondel C, Munteanu M, Moussalli J, Thibault V, Naveau S, Simon A, et al. A prospective assessment of an "a la carte" regimen of PEG interferon alfa 2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers. J Viral Hepat 2006;13:182-9.
46. Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, et al. The predictive value of FibroTest vs APRI for the diagnosis of fibrosis in chronic hepatitis C [letter]. Hepatology 2004;39:862-3.
47. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000;32:582-7.